Custom-Made vaccine trial offers new hope for Tough-to-Treat blood cancer

NCT ID NCT06799026

First seen Nov 01, 2025 · Last updated Apr 21, 2026 · Updated 27 times

Summary

This early-stage study is testing whether a personalized cancer vaccine made from a patient's own cells, when combined with an immunotherapy drug called elranatamab, is safe and effective for treating multiple myeloma that has returned or stopped responding to standard treatments. The trial will enroll 25 adults who have already tried at least three other therapies. Researchers will create a unique vaccine for each participant by fusing their cancer cells with their immune cells, aiming to train the body's defenses to attack the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beth Israel Deaconess Medical Center

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Dana-Farber Cancer Institute

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.